z-logo
Premium
The BCL 2 antagonist ABT ‐199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR 4 Wild‐type and CXCR 4 WHIM mutated Waldenstrom macroglobulinaemia cells
Author(s) -
Cao Yang,
Yang Guang,
Hunter Zachary R.,
Liu Xia,
Xu Lian,
Chen Jie,
Tsakmaklis Nickolas,
Hatjiharissi Evdoxia,
Kanan Sandra,
Davids Matthew S.,
Castillo Jorge J.,
Treon Steven P.
Publication year - 2015
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.13278
Subject(s) - ibrutinib , idelalisib , cytotoxicity , antagonist , apoptosis , chemistry , pharmacology , cancer research , medicine , receptor , in vitro , immunology , leukemia , biochemistry , chronic lymphocytic leukemia
Advani, R.H., Buggy, J.J., Sharman, J.P., Smith, S.M., Boyd, T.E., Grant, B., Kolibaba, K.S., Furman, R.R., Rodriguez, S., Chang, B.Y., Sukbuntherng, J., Izumi, R., Hamdy, A., Hedrick, E. & Fowler, N.H. (2013) Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. Journal of Clinical Oncology, 31, 88–94. Burger, J.A. & Buggy, J.J. (2013) Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765). Leukemia & Lymphoma, 54, 2385–2391. Byrd, J.C., Furman, R.R., Coutre, S.E., Flinn, I.W., Burger, J.A., Blum, K.A., Grant, B., Sharman, J.P., Coleman, M., Wierda, W.G., Jones, J.A., Zhao, W., Heerema, N.A., Johnson, A.J., Sukbuntherng, J., Chang, B.Y., Clow, F., Hedrick, E., Buggy, J.J., James, D.F. & O’Brien, S. (2013) Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. New England Journal of Medicine, 369, 32–42. Chang, B.Y., Francesco, M., De Rooij, M.F., Magadala, P., Steggerda, S.M., Huang, M.M., Kuil, A., Herman, S.E., Chang, S., Pals, S.T., Wilson, W., Wiestner, A., Spaargaren, M., Buggy, J.J. & Elias, L. (2013) Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood, 122, 2412–2424. Cheson, B.D., Byrd, J.C., Rai, K.R., Kay, N.E., O’Brien, S.M., Flinn, I.W., Wiestner, A. & Kipps, T.J. (2012) Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. Journal of Clinical Oncology, 30, 2820–2822. Cinar, M., Hamedani, F., Mo, Z., Cinar, B., Amin, H.M. & Alkan, S. (2013) Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis. Leukemia Research, 37, 1271– 1277. Davis, R.E., Ngo, V.N., Lenz, G., Tolar, P., Young, R.M., Romesser, P.B., Kohlhammer, H., Lamy, L., Zhao, H., Yang, Y., Xu, W., Shaffer, A.L., Wright, G., Xiao, W., Powell, J., Jiang, J.K., Thomas, C.J., Rosenwald, A., Ott, G., MullerHermelink, H.K., Gascoyne, R.D., Connors, J.M., Johnson, N.A., Rimsza, L.M., Campo, E., Jaffe, E.S., Wilson, W.H., Delabie, J., Smeland, E.B., Fisher, R.I., Braziel, R.M., Tubbs, R.R., Cook, J.R., Weisenburger, D.D., Chan, W.C., Pierce, S.K. & Staudt, L.M. (2010) Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature, 463, 88–92. Gauld, S.B., Dal Porto, J.M. & Cambier, J.C. (2002) B cell antigen receptor signaling: roles in cell development and disease. Science, 296, 1641–1642. Honigberg, L.A., Smith, A.M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D.H., Miller, R.A. & Buggy, J.J. (2010) The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proceedings of the National Academy of Sciences of the United States of America, 107, 13075–13080. Wang, M.L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B.S., Jurczak, W., Advani, R.H., Romaguera, J.E., Williams, M.E., Barrientos, J.C., Chmielowska, E., Radford, J., Stilgenbauer, S., Dreyling, M., Jedrzejczak, W.W., Johnson, P., Spurgeon, S.E., Li, L., Zhang, L., Newberry, K., Ou, Z., Cheng, N., Fang, B., McGreivy, J., Clow, F., Buggy, J.J., Chang, B.Y., Beaupre, D.M., Kunkel, L.A. & Blum, K.A. (2013) Targeting BTK with ibrutinib in relapsed or refractory mantlecell lymphoma. New England Journal of Medicine, 369, 507–516.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here